JAK ACADEMY in Rheumatoid Arthritis (RA)
JAK ACADEMY in Rheumatoid Arthritis (RA)
DOI:
https://doi.org/10.19156/abtpn.2018.0033Keywords:
Rheumatoid arthritis, JAKAbstract
The latest update of the EULAR recommendations for the treatment of RA maintain csDMARD (conventional systemic DMARDs) as the first line treatment, with methotrexate (MTX) still identified as the anchor drug, to which it is possible to add, in failure patients with negative prognostic factors, a biological drug or a tsDMARD (target synthetic DMARD), i.e JAK inhibitors.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 The authors
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors contributing to AboutOpen agree to publish their articles under the Creative Commons NonCommercial 4.0 International License (CC BY-NC 4.0), which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.